We recently compiled a list of the Jim Cramer Discusses These 11 Stocks & Finds Few Reasons To Sell. In this article, we are ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US counterparts.

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...